SLNO241220C60000
- 4.90
- +0.30+6.52%
Soleno Therapeutics Newsroom
Soleno Therapeutics Reports Q3 Progress and Financials
Express News | Soleno Therapeutics Announces Oral Presentations Featuring Diazoxide Choline Extended-Release (Dccr) Tablets in Prader-Willi Syndrome at Espe 2024
H.C. Wainwright Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $70
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Cantor Fitzgerald Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $67
Cantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)
Soleno Therapeutics Reports Q3 EPS($1.83) , Consensus (63c)
Soleno Therapeutics | 8-K: Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Soleno Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Express News | Soleno Therapeutics Q3 Basic EPS USD -1.83
Soleno Therapeutics Analyst Ratings
Oppenheimer Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $73
Soleno Therapeutics Price Target Raised to $73 From $65 at Oppenheimer
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
13D Filings -- Barron's
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93